Obsessive-compulsive disorder (OCD) is one of the most delayed diagnoses in psychiatry, and much of that delay happens in offices like ours. Patients typically notice their first symptoms in adolescence or early adulthood but are not correctly diagnosed until roughly a decade later. One outpatient study found an average of about 12.8 years between symptom onset and diagnosis, and a meta-analysis of 31 studies put the pooled duration of untreated illness at roughly 6.7 years.
That lag matters, because longer untreated illness is linked to a worse prognosis. Some of the delay comes from patients themselves, since the shame attached to taboo thoughts keeps people quiet. But a meaningful share comes from clinicians not recognizing it.
OCD travels with the very conditions it gets mistaken for. Among U.S. adults with OCD, 76 percent have a lifetime anxiety disorder and 63 percent a lifetime depressive or bipolar disorder. When a patient’s chief complaint is low mood or worry, the obsessive-compulsive engine underneath is easy to miss.
How OCD gets misread
The pattern of misreading is predictable:
- Intrusive thoughts get labeled as generalized anxiety. Yet the worries in generalized anxiety disorder are about real-life concerns and are rarely accompanied by compulsions. OCD thoughts are unwanted, feel foreign to the patient, and drive rituals.
- Compulsions get mistaken for personality. Checking, ordering, and reassurance-seeking are praised or excused as conscientiousness or perfectionism.
- The obsession stays hidden. A patient tormented by intrusive sexual, violent, or blasphemous thoughts often presents only with the resulting depression and secrecy, and will not mention the obsession unless asked directly.
Five questions that cut through
A few plain questions, drawn from the National Institute for Health and Care Excellence (NICE) screening set, uncover OCD quickly:
- Do you wash or clean a lot?
- Do you check things a lot?
- Is there a thought that keeps bothering you that you would like to get rid of but cannot?
- Do your daily activities take a long time to finish?
- Do you feel you have to arrange things in a particular order, and are you bothered by messiness?
A “yes” that causes distress should prompt a focused interview. Because suicide risk is elevated in OCD and patients may not disclose it, that interview should include screening for suicidal thoughts. Where a longer interview isn’t practical, ultra-brief self-report tools such as the Obsessive-Compulsive Inventory-4 (OCI-4) can help.
Real physician voices, twice a week
Free, and one click to unsubscribe.
OCD is treated differently
Getting the diagnosis right is only half the battle. OCD is treated differently from the depression and anxiety it masquerades as.
Therapy: The first-line psychotherapy is exposure and response prevention (ERP), a structured behavioral therapy in which patients face feared triggers while holding back from the compulsive response. Among patients who complete it, response rates reach as high as 70 percent.
Medication: SSRIs are first-line, but they behave differently in OCD than in mood disorders. They take longer to work, often 4 to 12 weeks, and typically require higher doses. In practice, that means pushing to the maximum tolerated dose within Food and Drug Administration (FDA) limits and holding an adequate trial for at least 8 to 12 weeks before calling it a failure. Fluoxetine, for example, is dosed at 20 to 60 mg/day for OCD, with up to 80 mg/day tolerated in studies, compared with a 20 mg/day target for depression.
Only about 40 to 65 percent of patients respond to a first SSRI, and full remission on medication alone is uncommon. That is why combining ERP with an SSRI is often the strongest approach.
When standard treatment isn’t enough
For patients who don’t respond adequately to medication and therapy, interventional options now exist. In 2018, the FDA cleared deep transcranial magnetic stimulation (dTMS) for OCD. The device uses an H-shaped coil to target brain regions involved in OCD. The clearance was based on a multicenter sham-controlled trial in which 38 percent of patients receiving active treatment responded, compared with 11 percent receiving sham, with response rising to 45 percent at one-month follow-up. A later meta-analysis of randomized trials in treatment-resistant OCD confirmed significantly higher response rates with active dTMS and no serious adverse events.
The sequence that serves these patients best mirrors how most of us already practice. Medication and ERP come first, optimized to an adequate dose and duration, and neuromodulation is reserved for those who remain symptomatic.
But the simplest, highest-yield change most of us can make comes earlier: asking the handful of screening questions that keep OCD from hiding in plain sight for another decade.
Ravi Singareddy is the founder and medical director of Empower Psychiatry & Sleep in north metro Atlanta, where he leads an interventional psychiatry practice offering transcranial magnetic stimulation (TMS) and Spravato (esketamine) for treatment-resistant depression. Double board-certified in psychiatry and sleep medicine, he brings more than two decades of clinical and academic experience to patients who haven’t found relief with medications alone. He is affiliated with Emory Healthcare.
His interest in neuromodulation dates back to his years as associate professor of psychiatry at Penn State College of Medicine. There, he taught annually on vagus nerve stimulation and novel depression therapies, and he published on long-term combined electroconvulsive therapy and vagus nerve stimulation in the American Journal of Psychiatry. He has authored numerous peer-reviewed papers on sleep disorders, insomnia, anxiety, and depression, with work appearing in Sleep, the Journal of Clinical Sleep Medicine, and Psychiatry Research.
Singareddy is a Fellow of the American Psychiatric Association and the American Academy of Sleep Medicine and practices measurement-based care, tracking outcomes to guide every treatment decision. He shares updates on Instagram.
